

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:03:43 ON 26 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

Point of Contact:
Jan Delaval
Librarian-Physical Sciences
CM1 1E04 Tel: 308-4498

STRUCTURE FILE UPDATES: 25 NOV 2001 HIGHEST RN 371755-13-4
DICTIONARY FILE UPDATES: 25 NOV 2001 HIGHEST RN 371755-13-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can ll

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 50-99-7 REGISTRY

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN (+)-Glucose

CN Anhydrous dextrose

CN Cartose

CN Cerelose

CN Cerelose 2001

CN Corn sugar

CN D(+)-Glucose

CN D-glucose

CN Dextropur

CN Dextrose

CN Dextrosol

CN Glucolin

CN Glucose

CN Glucosteril

CN Goldsugar

CN Grape sugar

CN Maxim Energy Gel

CN Staleydex 111

CN Staleydex 333

CN Sugar, grape

CN Tabfine 097(HS)

CN Vadex

FS STEREOSEARCH

DR 8012-24-6, 8030-23-7, 162222-91-5, 165659-51-8, 50933-92-1, 80206-31-1

MF C6 H12 O6

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU,
DETERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB,
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC,
PDLCOM*, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT,
TULSA, ULIDAT, USAN, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

115781 REFERENCES IN FILE CA (1967 TO DATE)
 1904 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 115916 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 135:335201
 REFERENCE 2: 135:335196
 REFERENCE 3: 135:335186
 REFERENCE 4: 135:335158
 REFERENCE 5: 135:335157
 REFERENCE 6: 135:335150
 REFERENCE 7: 135:335080
 REFERENCE 8: 135:335033
 REFERENCE 9: 135:335013
 REFERENCE 10: 135:334997

=> d ide can 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 9004-10-8 REGISTRY

CN **Insulin (9CI)** (CA INDEX NAME)

OTHER NAMES:

CN Actrapid

CN Actrapid HM

CN Actrapid MC

CN Decurvon

CN Endopancrine

CN Iletin

CN Insular

CN Insulin Injection

CN Insulyl

CN Iszilin

DR 8049-67-0, 8049-95-4, 9004-12-0, 9045-63-0, 9045-65-2, 9045-66-3,
 9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8, 37243-75-7,
 37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
 CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,
 CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA,
 PROMT, RTECS*, TOXCENTER, TOXLIT, USAN, USPATFULL, VTB
 (*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

69517 REFERENCES IN FILE CA (1967 TO DATE)

1416 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

69598 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:335183

REFERENCE 2: 135:335149

REFERENCE 3: 135:335147

REFERENCE 4: 135:335111

REFERENCE 5: 135:335089

REFERENCE 6: 135:332192

REFERENCE 7: 135:332177

REFERENCE 8: 135:330911

REFERENCE 9: 135:330910

REFERENCE 10: 135:330899

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 09:03:55 ON 26 NOV 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 26 Nov 2001 VOL 135 ISS 23

FILE LAST UPDATED: 25 Nov 2001 (20011125/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d all tot 179

L79 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 2001:375303 HCAPLUS

DN 134:337912

TI System for the **extrapolation** of **glucose** concentration
for determining **insulin** dosage

IN Kalatz, Brit; Hoss, Udo

PA Roche Diagnostics G.m.b.H., Germany

SO Ger. Offen., 14 pp.

CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61B005-00
 ICS A61B005-15; G01N033-48; G01N035-00
 CC 9-1 (Biochemical Methods)
 Section cross-reference(s): 14, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10057215	A1	20010523	DE 2000-10057215	20001117
	JP 2001204817	A2	20010731	JP 2000-351415	20001117
PRAI	DE 1999-19955734	A1	19991118		

AB The invention concerns a system that contains units to record and store data on time and amt. of **insulin** administration, time and amt. of carbohydrate intake, measured **glucose** concn. values and time of measurement; the data are used in a formula to extrapolate **glucose** concn. and to det. the next **insulin** dosage. The system is integrated with the blood sampling unit and the **insulin** dosage unit; **insulin** dosage and carbohydrate intake control is based on the extrapolated data.

ST **glucose** concn extrapolation system **insulin** dosage
diabetes mellitus

IT Medical goods
 (glucose concn. extrapolation unit; system for extrapolation of **glucose** concn. for detg. **insulin** dosage)

IT **Algorithm**
Blood analysis
Diabetes mellitus

Diet

Process control

(system for extrapolation of **glucose** concn. for detg. **insulin** dosage)

IT **Carbohydrates, analysis**

RL: ANT (Analyte); FFD (Food or feed use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(system for extrapolation of **glucose** concn. for detg. **insulin** dosage)

IT 50-99-7, D-Glucose, analysis

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(blood; system for extrapolation of **glucose** concn. for detg. **insulin** dosage)

IT 9004-10-8, **Insulin**, biological studies

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(system for extrapolation of **glucose** concn. for detg. **insulin** dosage)

L79 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 2001:107374 HCAPLUS

DN 134:275986

TI A model for **glucose control** of
insulin secretion during 24 h of free living

AU Mari, Andrea; Camastra, Stefania; Toschi, Elena; Giancaterini, Annalisa; Gastaldelli, Amalia; Mingrone, Geltrude; Ferrannini, Ele

CS C.N.R. Institute of Systems Science and Biomedical Engineering, Padua, Italy

SO Diabetes (2001), 50(Suppl. 1), S164-S168

CODEN: DIAEAZ; ISSN: 0012-1797

PB American Diabetes Association

DT Journal

LA English

CC 2-6 (Mammalian Hormones)

AB The aim of this work was to develop a math. model describing the functional dependence of **insulin** secretion on plasma

glucose concns. during 24 h of free living. Hourly central venous blood samples were obtained from a group of healthy volunteers who spent 24 h in a calorimetric chamber, where they consumed standardized meals. **Insulin** secretory rates were reconstructed from plasma C-peptide concns. by deconvolution. The relation between **insulin** release and plasma **glucose** concns. was modeled as the sum of three components: a static component (describing the dependence on plasma **glucose** concn. itself, with an embedded circadian oscillation), a dynamic component (modeling the dependence on **glucose** rate of change), and a residual component (including the fraction of **insulin** secretion not explained by **glucose** levels). The model fit of the individual 24-h secretion profiles was satisfactory (within the assigned exptl. error of **glucose** and C-peptide concns.). The static component yielded a dose-response function in which **insulin** release increased quasi-linearly (from 40 to 400 pmol/min on av.) over the range of 4-9 mmol/l **glucose**. The dynamic component was different from zero in coincidence with meal-related **glucose** excursions. The circadian oscillation and the residual component accounted for the day/night difference in the ability of **glucose** to stimulate **insulin** release. Over 24 h, total **insulin** release averaged 257 nmol (or 43 U). The static and dynamic component together accounted for .apprx.80% of total **insulin** release. The model proposed here provides a detailed robust description of **glucose**-related **insulin** release during free-living conditions. In **nondiabetic** subjects, non-**glucose**-dependent **insulin** release is a small fraction of total **insulin** secretion.

ST **insulin** secretion **glucose** math model

IT **Blood plasma**

Secretion (process)

Simulation and Modeling, physicochemical

(a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

IT Rhythm, biological

(circadian; a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

IT Pancreatic islet of Langerhans

(.beta.-cell; a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

IT 50-99-7, D-Glucose, biological studies

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

IT 59112-80-0, C-Peptide

RL: BOC (Biological occurrence); BUU (Biological use, unclassified); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

IT 9004-10-8, **Insulin**, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(a math. model for **glucose** control of **insulin** secretion during a 24-h period of free living in humans)

RE.CNT 14

RE

(1) Byrne, M; Am J Physiol 1995, V268, PE21 HCAPLUS

(2) Cerasi, E; Carbohydrate Metabolism: Quantitative Physiology and Mathematical Modelling 1981, P3 HCAPLUS

(3) Dupre, J; J Clin Invest 1969, V48, P745 HCAPLUS

(4) Eaton, R; J Clin Endocrinol Metab 1980, V51, P520 HCAPLUS

(5) Ferrannini, E; J Clin Invest 1979, V64, P243 HCAPLUS

(6) Floyd, J; J Clin Invest 1966, V45, P1487 HCAPLUS

(7) Hovorka, R; Diabetologia 1998, V41, P548 HCAPLUS

(8) Hovorka, R; J Clin Endocrinol Metab 1998, V83, P744 HCAPLUS

- (9) Levitt, N; Metabolism 1993, V42, P829 HCAPLUS
- (10) Polonsky, K; J Clin Invest 1988, V81, P442 HCAPLUS
- (11) Robertson, R; J Clin Invest 1976, V57, P791 HCAPLUS
- (12) Van Cauter, E; Am J Physiol 1992, V262, PE467 HCAPLUS
- (13) Van Cauter, E; Diabetes 1992, V41, P368 HCAPLUS
- (14) Van Cauter, E; J Clin Invest 1991, V88, P934 HCAPLUS

L79 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 2000:879828 HCAPLUS

DN 134:249162

TI Novel control system for blood **glucose** using a model
predictive method

AU Kan, Shugen; Onodera, Hisashi; Furutani, Eiko; Aung, Tun; Araki, Mituhiko;
Nishimura, Haruo; Maetani, Shunzo; Imamura, Masayuki

CS Department of Surgery and Surgical Basic Science, Kyoto University, Kyoto,
606-8507, Japan

SO ASAIO J. (2000), 46(6), 657-662

CODEN: AJOUET; ISSN: 1058-2916

PB Lippincott Williams & Wilkins

DT Journal

LA English

CC 9-16 (Biochemical Methods)

Section cross-reference(s): 14

AB We developed a novel blood **glucose** control system, using a model
predictive method, to achieve optimal control of the blood **glucose**
level in severely **diabetic** or pancreatectomized patients. This
system is designed to predict **glucose** level changes in advance,
considering delayed response time and the administered doses of
insulin. This method is also designed to calc. the most
appropriate **insulin** infusion rate by considering differences in
individual response to **insulin**. In this study, we compared our
system with a conventional proportional and differential controller (PD
controller) to det. whether the new system could regulate the
glucose level efficiently in pancreatectomized dogs. The model
predictive control method resulted in a significant redn. of mean
insulin infusion rate compared with the conventional PD controller
(0.71 mU/kg per min vs. 1.81 mU/kg per min, $p = 0.0005$), when the
glucose level in both methods reached the planned target level
(100 mg/dL). The new system also tended to have a reduced mean
glucose infusion rate for compensating for overshooting of the
glucose level compared with the PD controller (0.7 mg/kg per min
vs. 1.1 mg/kg per min, $p = 0.16$). These results indicate that the new
system should be a useful tool for regulating the **glucose** level
in severely **diabetic** patients.

ST blood **glucose insulin** control system model

IT **Blood analysis**

Diabetes mellitus

Process control

Simulation and Modeling, biological

Simulation and Modeling, physicochemical

(control system for blood **glucose** using a model predictive
method)

IT 50-99-7, D-Glucose, analysis

RL: ANT (Analyte); ANST (Analytical study)

(blood; control system for blood **glucose** using a model
predictive method)

IT 9004-10-8, **Insulin**, biological studies

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(control system for blood **glucose** using a model predictive
method)

RE.CNT 24

RE

(1) Albisser, A; Proc IEEE 1979, V67, P1308

(2) Anon; Advances in Model-Based Predictive Control 1994

(3) Anon; Model Predictive Control in the Process Industry 1995

- (4) Anon; Predictive Control: A Unified Approach 1992
- (5) Arnold, M; Anal Chem 1998, V70, P1773 HCAPLUS
- (6) Furutani, E; IEEE Trans Biomed Eng 1995, V42, P999 MEDLINE
- (7) Gerritsen, M; J Invest Surg 1988, V11, P163
- (8) Goriya, Y; Med Prog Technol 1979, V6, P99 MEDLINE
- (9) Heise, H; Cell Mol Biol 1998, V44, P899 HCAPLUS
- (10) Kaplan, N; Arch Intern Med 1989, V149, P1514 HCAPLUS
- (11) Kawamori, R; Acta Endocrinol 1978, V87, P339 HCAPLUS
- (12) Kienitz, K; IEEE Trans Biomed Eng 1993, V40, P1133 MEDLINE
- (13) Klonoff, D; Diabetes Care 1997, V20, P433 MEDLINE
- (14) Muller, U; Int J Artif Organs 1997, V20, P285 MEDLINE
- (15) Nomura, M; Comput Biomed Res 1984, V17, P570 HCAPLUS
- (16) Ollerton, R; Proc of the 12th Triennial World Congress of Int Federation of Automat Contr 1993, V4, P463
- (17) Onodera, H; World J Surg 1999, V23, P1258 MEDLINE
- (18) Parker, R; IEEE Trans Biomed Eng 1999, V46, P148 MEDLINE
- (19) Reaven, G; Diabetes 1988, V37, P1595 MEDLINE
- (20) Sakamoto, T; Artif Organs 1994, V4, P141
- (21) Shichiri, M; Artif Organs 1998, V22, P32 HCAPLUS
- (22) Shichiri, M; Lancet 1982, V2, P1129 HCAPLUS
- (23) Shimoda, S; Front Med Biol Eng 1997, V8, P197 MEDLINE
- (24) Trajanoski, Z; Comput Methods Programs Biomed 1996, V50, P265 MEDLINE

L79 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 2000:84269 HCAPLUS

DN 133:145188

TI Validation of the **insulin** sensitivity index (ISI0,120): comparison with other **measures**

AU Gutt, M.; Davis, C. L.; Spitzer, S. B.; Llabre, M. M.; Kumar, M.; Czarnecki, E. M.; Schneiderman, N.; Skyler, J. S.; Marks, J. B.

CS Behavioral Medicine Research Center, University of Miami, Miami, FL, USA

SO Diabetes Res. Clin. Pract. (2000), 47(3), 177-184

CODEN: DRCPE9; ISSN: 0168-8227

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

CC 2-6 (Mammalian Hormones)

Section cross-reference(s): 14

AB The purpose of this study was to explore possible calcns. using oral **glucose** tolerance test (OGTT) values to develop a simple measure of **insulin** sensitivity. A formula for an **insulin** sensitivity index, ISI0,120, that uses the fasting (0 min) and 120 min post-oral **glucose** (OGTT) **insulin** and **glucose** concns. was devised. It appears to be generalizable across a spectrum of **glucose** tolerance and obesity. Most importantly, the data show that ISI0,120 correlates well, when applied prospectively in comparative studies, with the **insulin** sensitivity index obtained from the **euglycemic** hyperinsulinemic clamp. This correlation was demonstrably superior to other indexes of **insulin** sensitivity such as the HOMA formula presented by Matthews, and performed comparably to the computerized HOMA index. Measurement of **insulin** sensitivity has traditionally been possible only in research settings because of the invasiveness and expense of the methods used. Clin. investigators have therefore sought more practical methods to obtain an index of **insulin** sensitivity. Such an index should approx. **insulin** sensitivity as measured by the **euglycemic** hyperinsulinemic clamp (M). Therefore, ISI0,120 is presented as a simple yet sensitive measure of **insulin** sensitivity which is adaptable for use in clin. settings as well as large epidemiol. studies.

ST **insulin** sensitivity oral **glucose** tolerance test calcn

IT **Diabetes** mellitus

Epidemiology

Mathematical methods

Obesity

Starvation, animal

(validation of **insulin** sensitivity index (ISI0,120) as a

measure of **insulin** sensitivity in humans)
IT Pancreatic islet of Langerhans
(.beta.-cell; validation of **insulin** sensitivity index
(ISI0,120) as a measure of **insulin** sensitivity in humans)
IT 9004-10-8, **Insulin**, biological studies
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(validation of **insulin** sensitivity index (ISI0,120) as a
measure of **insulin** sensitivity in humans)
IT 50-99-7, D-**Glucose**, biological studies
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological
study); PROC (Process); USES (Uses)
(validation of **insulin** sensitivity index (ISI0,120) as a
measure of **insulin** sensitivity in humans)
RE.CNT 24
RE
(1) Anderson, R; Am J Epidemiol 1995, V142, P724 MEDLINE
(2) Anon; Guidance for Treatment of Adult Obesity, Shape Up America! 1996, P8
(3) Bergman, R; J Clin Invest 1987, V79, P790 HCAPLUS
(4) Cederholm, J; Diab Res Clin Pract 1990, V10, P167 MEDLINE
(5) Cohen, J; Applied Multiple Regression/Correlation Analysis for the
Behavioral Sciences 1983, P56
(6) DeFronzo, R; Am J Physiol 1979, V237, PE214 HCAPLUS
(7) Dix, D; Acta Diabetol Lat 1981, V18, P21 HCAPLUS
(8) Gutt, M; Endocrine Society Program & Abstracts 1998, P465
(9) Gutt, M; The Endocrine Society Program & Abstracts 1997, P476
(10) Haffner, S; Diabetes 1995, V44, P1386 HCAPLUS
(11) Haffner, S; Diabetes Care 1997, V20, P1087 MEDLINE
(12) Harano, Y; J Clin Endocrinol Metab 1977, V45, P1124 HCAPLUS
(13) Hollenbeck, C; Diabetes 1984, V33, P460 HCAPLUS
(14) Hosker, J; Diabetologia 1985, V28, P401 HCAPLUS
(15) Kadowaki, T; Diabetologia 1984, V26, P44 MEDLINE
(16) Laakso, M; Am J Epidemiol 1993, V137, P959 MEDLINE
(17) Levy, J; Diabetes Care 1998, V12, P2191
(18) Matthews, D; Diabetologia 1985, V28, P412 HCAPLUS
(19) National Diabetes Data Group; Diabetes 1979, V28, P1039
(20) Perley, M; Diabetes 1966, V15, P867 HCAPLUS
(21) Seltzer, H; J Clin Invest 1967, V46, P323 HCAPLUS
(22) Shen, S; J Clin Invest 1970, V49, P2151 HCAPLUS
(23) The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus; Diabetes Care 1997, V20, P1183
(24) Voors, A; Am J Epidemiol 1980, V113, P347

L79 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:593848 HCAPLUS
DN 131:308495
TI Noninvasive prediction of **glucose** by near-infrared diffuse
reflectance spectroscopy
AU Malin, Stephen F.; Ruchti, Timothy L.; Blank, Thomas B.; Thennadil, Suresh
N.; Monfre, Stephen L.
CS **Instrumentation Metrics, Incorporated, Tempe, AR, 85284, USA**
SO Clin. Chem. (Washington, D. C.) (1999), 45(9), 1651-1658
CODEN: CLCHAU; ISSN: 0009-9147
PB American Association for Clinical Chemistry
DT Journal
LA English
CC 9-5 (Biochemical Methods)
AB Background: Self-monitoring of blood **glucose** by
diabetics is crucial in the redn. of complications related to
diabetes. Current monitoring techniques are invasive and painful,
and discourage regular use. The aim of this study was to demonstrate the
use of near-IR (NIR) diffuse reflectance over the 1050-2450 nm wavelength
range for noninvasive monitoring of blood **glucose**. Methods: Two
approaches were used to develop calibration models for predicting the
concn. of blood **glucose**. In the first approach, seven
diabetic subjects were studied over a 35-day period with random

collection of NIR spectra. Corresponding blood samples were collected for analyte anal. during the collection of each NIR spectrum. The second approach involved three **nondiabetic** subjects and the use of oral **glucose** tolerance tests (OGTTs) over multiple days to cause fluctuations in blood **glucose** concns. Twenty NIR spectra were collected over the 3.5-h test, with 16 corresponding blood specimens taken for analyte anal. Results: Statistically valid calibration models were developed on three of the seven **diabetic** subjects. The mean std. error of prediction through cross-validation was 1.41 mmol/L (25 mg/dL). The results from the OGTT testing of three **nondiabetic** subjects yielded a mean std. error of calibration of 1.1 mmol/L (20 mg/dL). Validation of the calibration model with an independent test set produced a mean std. error of prediction equiv. to 1.03 mmol/L (19 mg/dL). Conclusions: These data provide preliminary evidence and allow cautious optimism that NIR diffuse reflectance spectroscopy using the 1050-2450 nm wavelength range can be used to predict blood **glucose** concns. noninvasively. Substantial research is still required to validate whether this technol. is a viable tool for long-term home diagnostic use by **diabetics**.

ST **diabetes glucose** near IR diffuse reflectance spectroscopy

IT **Blood analysis**

(**glucose**; noninvasive prediction of **glucose** by near-IR diffuse reflectance spectroscopy)

IT Diffuse reflectance IR spectroscopy

(near-IR; noninvasive prediction of **glucose** by near-IR diffuse reflectance spectroscopy)

IT **Diabetes mellitus**

(noninvasive prediction of **glucose** by near-IR diffuse reflectance spectroscopy)

IT **50-99-7, D-Glucose, analysis**

RL: ANT (Analyte); ANST (Analytical study)

(anal.; noninvasive prediction of **glucose** by near-IR diffuse reflectance spectroscopy)

RE.CNT 27

RE

- (1) Anderson, R; J Investig Dermatol 1981, V77, P13 HCAPLUS
- (2) Arnold, M; Anal Chem 1990, V62, P1457 HCAPLUS
- (3) Arnold, M; Anal Chem 1998, V70, P1773 HCAPLUS
- (4) Burmeister, J; Human non-invasive measurement of glucose using near infrared spectroscopy 1998
- (5) Cheong, W; IEEE J Quantum Electron 1990, V26, P2166
- (6) Danzer, K; LEOS Newslett 1998, V12, P9
- (7) Fischbacher, C; Fresenius J Anal Chem 1997, V359, P78 HCAPLUS
- (8) Geladi, P; Anal Chim Acta 1986, V185, P1 HCAPLUS
- (9) Geladi, P; Appl Spectrosc 1985, V39, P491
- (10) Hazen, K; [PhD Thesis]. University of Iowa 1995
- (11) Heise, H; Artif Org 1994, V18, P439 HCAPLUS
- (12) Heise, H; SPIE Proc 1994, V2089, P114
- (13) Jagemann, K; Z Phys Chem 1995, V191S, P179
- (14) Khalil, O; Clin Chem 1999, V45, P165 HCAPLUS
- (15) Marbach, R; Appl Optics 1995, V34, P610
- (16) Marbach, R; Appl Spectrosc 1993, V47, P875 HCAPLUS
- (17) Martens, H; Multivariate calibration 1989
- (18) Martin, K; J Soc Cosmet Chem 1993, V44, P249
- (19) Massart, D; Chemometrics: a textbook 1988
- (20) Muller, U; Int J Artif Organs 1997, V20, P285 MEDLINE
- (21) National Institutes of Health; Diabetes statistics 1997
- (22) Pan, S; Anal Chem 1996, V68, P1124 HCAPLUS
- (23) Robinson, M; Clin Chem 1992, V38, P1618 HCAPLUS
- (24) Savitzky, A; Anal Chem 1964, V36, P1627 HCAPLUS
- (25) The Diabetes Control and Complications Trial Research Group; N Engl J Med 1993, V329, P977
- (26) Van Gemert, M; IEEE Trans Biomed Eng 1989, V36, P1146 MEDLINE
- (27) Ward, K; Appl Spectrosc 1992, V46, P959 HCAPLUS

L79. ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:370787 HCAPLUS
 DN 131:153817
 TI **Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state**
 AU Avignon, A.; Boegner, C.; Mariano-Goulart, D.; Colette, C.; Monnier, L.
 CS Department of Metabolism, Lapeyronie Hospital, University Hospital of Montpellier, Montpellier, 34295, Fr.
 SO Int. J. Obes. (1999), 23(5), 512-517
 CODEN: IJOBDP; ISSN: 0307-0565
 PB Stockton Press
 DT Journal
 LA English
 CC 2-1 (Mammalian Hormones)
 Section cross-reference(s): 14
 AB Studies were carried out to compare **insulin** sensitivity indexes derived from plasma **insulin** (I) and **glucose** (G) in the basal state (Sib) and at the second hour (I2h and G2h) of an oral **glucose** tolerance test (OGTT, Si2h) (i) with measurements of **insulin** sensitivity using the **insulin** modified frequently sampled i.v. **glucose** tolerance test (FSIVGTT) [Si(IVGTT)] and (ii) with modeling of fasting **glucose** and **insulin** by the homeostasis model assessment (HOMA). Forty seven subjects entered the study, 31 subjects were classified as having normal **glucose** tolerance (NGT), 10 as having impaired tolerance to **glucose** (IGT) and six as type 2 **diabetes** mellitus according to the World Health Organization (WHO) criteria. Sib and Si2h were calcd. as follows: $sib = 108 / (I \cdot G \cdot VD)$, $Si2h = 108 / (I2h \cdot G2h \cdot VD)$ where VD is an est. of the apparent **glucose** distribution vol. A third **insulin** sensitivity index (SiM) was calcd. by averaging Sib and Si2h. HOMA was calcd. as follows: $I / (22.5 \cdot e^{-\ln G})$. Si(IVGTT) Sib, Si2h and SiM were all significantly higher in subjects with NGT than in those with IGT or type 2 **diabetes**. Si(IVGTT) was highly correlated with the three **insulin** sensitivity indexes found in the total population, in subjects with NGT and in those with IGT. In type 2 **diabetic** patients, a significant correlation was only noted when SiM was tested against Si(IVGTT). In most circumstances, the assocns. of Si(IVGTT) with Sib, Si2h and SiM were stronger than the corresponding assocns. with Ib, I2h or HOMA. SiM was the index that correlated best with Si(IVGTT) in the whole group ($r = 0.92$) as well as in NGT ($r = 0.86$), IGT ($r = 0.96$) and type 2 **diabetes** ($r = 0.83$) subgroups. Calcns. of sensitivity indexes from G and I concns. in the basal state and during a conventional 2 h OGTT appear to be useful for coupling in the same simple and single test both a detn. of **glucose** tolerance and an est. of **insulin** sensitivity.
 ST **insulin** sensitivity estn blood **glucose** fasting;
diabetes **insulin** sensitivity estn blood **glucose** fasting
 IT **Blood plasma**
 Fasting
 Simulation and Modeling, biological
 Stomach content
 (assessment of **insulin** sensitivity from plasma **insulin** and **glucose** in fasting or post oral **glucose**-load state in humans)
 IT **Diabetes** mellitus
 (non-**insulin**-dependent; assessment of **insulin** sensitivity from plasma **insulin** and **glucose** in fasting or post oral **glucose**-load state in humans in **diabetes**)
 IT 9004-10-8, **Insulin**, biological studies
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 (assessment of **insulin** sensitivity from plasma

insulin and glucose in fasting or post oral
glucose-load state in humans)

IT 50-99-7, D-Glucose, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(blood; assessment of insulin sensitivity from plasma
insulin and glucose in fasting or post oral
glucose-load state in humans)

IT 50-99-7, D-Glucose, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BIOL (Biological study); PROC (Process)
(tolerance; assessment of insulin sensitivity from plasma
insulin and glucose in fasting or post oral
glucose-load state in humans)

RE.CNT 31

RE

(1) Anderson, R; Am J Epidemiol 1995, V142, P724 MEDLINE
(2) Anderson, R; Diabetes 1994, V43, P27A
(3) Bergman, R; Am J Physiol 1979, V236, PE667 HCAPLUS
(4) Bergman, R; J Clin Invest 1987, V79, P790 HCAPLUS
(5) Coates, P; Diabetes 1995, V42, P1635
(6) Coates, P; Diabetes 1995, V44, P631 HCAPLUS
(7) Cobelli, C; Am J Physiol 1987, V252, PE679 HCAPLUS
(8) DeFronzo, R; Am J Physiol 1979, V237, PE214 HCAPLUS
(9) DeFronzo, R; Diabetes 1988, V37, P667 MEDLINE
(10) Del Prato, S; Lancet 1996, V347, P132 MEDLINE
(11) Duncan, M; Lancet 1995, V346, P120 MEDLINE
(12) Eriksson, J; N Engl J Med 1989, V321, P337 MEDLINE
(13) Ferrannini, E; J Clin Invest 1997, V100, P1166 HCAPLUS
(14) Ferrannini, E; N Engl J Med 1987, V317, P350 MEDLINE
(15) Golay, A; Diab Metab 1994, V20, P3 MEDLINE
(16) Kahn, S; Diabetes 1993, V42, P1663 HCAPLUS
(17) Kuczmarski, R; JAMA 1994, V272, P205 MEDLINE
(18) Laakso, M; Am J Epidemiol 1993, V137, P959 MEDLINE
(19) Lillioja, S; N Engl J Med 1993, V329, P1988 MEDLINE
(20) Manson, J; N Engl J Med 1990, V322, P882 MEDLINE
(21) Matthews, D; Diabetologia 1985, V28, P412 HCAPLUS
(22) Rabinowitz, D; J Clin Invest 1962, V12, P2173
(23) Reaven, G; Diabetes 1988, V37, P1595 MEDLINE
(24) Reaven, G; Diabetologia 1989, V32, P52 HCAPLUS
(25) Saad, M; Diabetes 1994, V43, P1114 HCAPLUS
(26) Shinozaki, K; Diabetes Care 1996, V19, P1 MEDLINE
(27) The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus; Diabetes Care 1997, V20, P1183
(28) Ward, W; Diabetes Care 1984, V7, P491 HCAPLUS
(29) World Health Organization; Diabetes Mellitus: Report of a WHO Study Group
1985
(30) Yki-Jarvinen, H; Diabetologia 1995, V38, P1378 MEDLINE
(31) Zar, J; Biostatistical analysis (2nd edn) 1984

L79 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:317872 HCAPLUS
DN 131:113372
TI Prediction of blood glucose levels in diabetic
patients using a hybrid AI technique
AU Liszka-Hackzell, Jan John
CS Department of Medical Informatics, University of Linkoping, Linkoping,
S-581 83, Swed.
SO Comput. Biomed. Res. (1999), 32(2), 132-144
CODEN: CBMRB7; ISSN: 0010-4809
PB Academic Press
DT Journal
LA English
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 14
AB One of the problems in the management of the diabetic patient is
to balance the dose of insulin without exactly knowing how the

patient's blood **glucose** concn. will respond. Being able to predict the blood **glucose** level would simplify the management. This paper describes an attempt to predict blood **glucose** levels using a hybrid AI technique combining the principal component method and neural networks. With this approach, no complicated models or algorithms need be considered. The results obtained from this fairly simple model show a correlation coeff. of 0.76 between the obsd. and the predicted values during the first 15 days of prediction. By using this technique, all the factors affecting this patient's blood **glucose** level are considered, since they are integrated in the data collected during this time period. It must be emphasized that the present method results in an individual model, valid for that particular patient under a limited period of time. However, the method itself has general validity, since the blood **glucose** variations over time have similar properties in any **diabetic** patient. (c) 1999 Academic Press.

ST blood **glucose** **diabetic** hybrid AI technique

IT **Blood analysis**

(**glucose**; prediction of blood **glucose** levels in **diabetic** patients using a hybrid AI technique)

IT **Simulation and Modeling, physicochemical**

(neural network; prediction of blood **glucose** levels in **diabetic** patients using a hybrid AI technique)

IT **Algorithm**

Blood analysis

Diabetes mellitus

Principal component analysis

(prediction of blood **glucose** levels in **diabetic** patients using a hybrid AI technique)

IT 50-99-7, D-Glucose, analysis

RL: ANT (Analyte); ANST (Analytical study)

(anal.; prediction of blood **glucose** levels in **diabetic** patients using a hybrid AI technique)

IT 50-99-7, D-Glucose, analysis

RL: ANT (Analyte); ANST (Analytical study)

(prediction of blood **glucose** levels in **diabetic** patients using a hybrid AI technique)

RE.CNT 11

RE

- (1) Andreassen, S; Comput Methods Programs Biomed 1994, V41, P153 MEDLINE
- (2) Chatfield, C; Introduction to Multivariate Analysis 1992
- (3) Chui, C; An Introduction to Wavelets 1992
- (4) Chui, C; Wavelets: Theory Algorithms and Applications 1994
- (5) Deutsch, T; Comput Methods Programs Biomed 1994, V41, P167 MEDLINE
- (6) Erkki, O; Principal Components Minor Components and Linear Neural Networks 1992, V5, P927
- (7) Lagoutte, D; J Atmos Terr Phys 1992, V54, P1283
- (8) Lehmann, E; Comput Methods Programs Biomed 1994, V41, P183 MEDLINE
- (9) Liszka, L; "Modelling of Pseudo-Indeterministic Processes Using Neural Networks" Invited lecture at the International Workshop on Artificial Intelligence Applications in Solar-Terrestrial Physics 1993
- (10) Liszka-Hackzell, J; Proceedings of the 1995 Computers in Cardiology
- (11) Rumelhart, D; "Parallel Distributed Processing: Explorations in the Microstructure of Cognition" "Foundations" 1986, VI

L79 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1999:135211 HCAPLUS

DN 130:347663

TI Controlled oral **glucose** tolerance test: evaluation of **insulin** resistance with an **insulin** infusion algorithm that forces the OGTT **glycemic** curve within the normal range. A feasibility study

AU Volpicelli, G.; Iannello, S.; Belfiore, F.

CS Chair of Internal Medicine, Institute of Medicina Interna e Specialita Internistiche, Medical School, University of Catania, Catania, Italy

SO Clin. Physiol. (1999), 19(1), 32-44

CODEN: CLPHDU; ISSN: 0144-5979

PB . Blackwell Science Ltd.

DT Journal

LA English

CC . 2-6 (Mammalian Hormones)

Section cross-reference(s): 14

AB This is a tech. study to show the feasibility of a computer-controlled oral **glucose** tolerance test (OGTT) using a specific algorithm, consisting of an OGTT carried out while **insulin** is infused as required to keep **glycemia** within the normal range (National **Diabetes** Data Group 1979 criteria). This technique allows (a) the amt. of **insulin** (**insulin** area) required to maintain a normal **glycemic** curve to be assessed, a parameter indicating the degree of **insulin** resistance; and (b) the unique parameter consisting of the **insulin** secretory response (C-peptide) to a normal **glycemic** curve under the inhibitory feedback exerted by the **insulin** levels required to maintain normal **glycemia** to be obtained. Preliminary results confirmed the feasibility of this approach by showing that during the test while the **glycemic** area was kept normal the insulinemic area (endogenous + infused **insulin**) increased markedly in obese and obese **diabetic** subjects compared with normal subjects, with values of 145.10, 204.75 and 68.25 nmol I-1 min-1 resp. (in both instances). In contrast, endogenous **insulin** secretion (C-peptide level) remained almost unchanged. Compared with data in normal subjects, free fatty acid (FFA) values were basally elevated in the obese and obese **diabetic** patients, and underwent a smaller decrease during the test. The FFA area were greater than normal in both groups of patients, suggesting that FFAs were not fully suppressible despite the highest possible **insulin** levels (higher **insulin** levels would produce **hypoglycemia**). The computer-controlled OGTT might be useful for the metabolic study of patients in the clin. setting.

ST **glucose** tolerance test algorithm **insulin** resistance

IT **Algorithm**

Computer application

Diabetes mellitus

Diagnosis

Insulin resistance

Obesity

(computer-controlled oral **glucose** tolerance test for evaluation of **insulin** resistance in relation to normal, obese and obese **diabetic** humans)

IT **Blood glucose**

Fatty acids, biological studies

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(computer-controlled oral **glucose** tolerance test for evaluation of **insulin** resistance in relation to normal, obese and obese **diabetic** humans)

IT 9004-10-8, **Insulin**, biological studies

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)

(computer-controlled oral **glucose** tolerance test for evaluation of **insulin** resistance in relation to normal, obese and obese **diabetic** humans)

IT 59112-80-0, Proinsulin C-peptide

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(computer-controlled oral **glucose** tolerance test for evaluation of **insulin** resistance in relation to normal, obese and obese **diabetic** humans)

IT 50-99-7, D-Glucose, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(computer-controlled oral **glucose** tolerance test for evaluation of **insulin** resistance in relation to normal, obese and obese **diabetic** humans)

RE.CNT 46

RE

- (1).Akanji, A; Diabetologia 1987, V30, P431 HCAPLUS
- (2) Alford, F; Diabetologia 1971, V7, P173 HCAPLUS
- (3) Andres, R; Automation in Analytical Chemistry 1966, P486 HCAPLUS
- (4) Bergman, R; Am J Physiol 1979, V236, PE667 HCAPLUS
- (5) Bergman, R; Diabetes 1989, V38, P1512 HCAPLUS
- (6) Bergman, R; J Clin Invest 1981, V68, P1456 HCAPLUS
- (7) Bonadonna, R; Am J Physiol 1989, V257, PE49 HCAPLUS
- (8) Bonora, E; J Clin Endocrinol Metab 1989, V68, P374 MEDLINE
- (9) Broekhuysen, H; IEEE Trans Biomed Eng 1981, V28, P678 MEDLINE
- (10) Cerasi, E; Diabetes 1972, V21, P224 MEDLINE
- (11) Cobelli, C; Math Biosci 1982, V58, P27 HCAPLUS
- (12) Cobelli, C; Med Biol Eng Comput 1980, V18, P457 HCAPLUS
- (13) De Fronzo, R; Am J Physiol 1979, V237, PE214 HCAPLUS
- (14) De Fronzo, R; Diabetes 1988, V37, P667 MEDLINE
- (15) Ferrannini, E; J Clin Invest 1983, V72, P1737 HCAPLUS
- (16) Fisher, U; Int J Artif Organs 1985, V9, P173
- (17) Freeman, H; J Clin Endocrinol 1942, V2, P431
- (18) Ganda, O; Diabetes 1978, V27, P715 HCAPLUS
- (19) Glantz, S; Primer of Biostatistics 1988
- (20) Groop, L; J Clin Invest 1991, V87, P83 HCAPLUS
- (21) Hales, C; Lancet 1963, V1, P200 MEDLINE
- (22) Harano, Y; J Clin Endocrinol Metab 1977, V45, P1124 HCAPLUS
- (23) Harding, P; Clin Endocrinol 1973, V2, P387 HCAPLUS
- (24) Harris, P; Diab Nutr Metab 1991, V4, P293
- (25) Hosker, J; Diabetologia 1985, V28, P401 HCAPLUS
- (26) Insel, P; J Clin Invest 1975, V55, P1057 HCAPLUS
- (27) Kaneko, T; Endocrinol Japan 1974, V21, P141 HCAPLUS
- (28) Luzi, L; Am J Physiol 1989, V257, PE241 HCAPLUS
- (29) McDonald, G; Diabetes 1965, V14, P473 MEDLINE
- (30) National Diabetes Data Group; Diabetes 1979, V28, P1039
- (31) Nuutila, P; J Clin Invest 1992, V89, P1767 HCAPLUS
- (32) Olefsky, J; Diabetes 1974, V23, P449 MEDLINE
- (33) Pfeiffer, E; Horm Metab Res 1974, V6, P339 MEDLINE
- (34) Piatti, P; Metabolism 1991, V40, P926 HCAPLUS
- (35) Porro, G; Progress in Artificial Organs 1985 1986, P682
- (36) Randle, P; Diabetologia 1994, V37(Suppl 2), PS155
- (37) Randle, P; Lancet 1963, V1, P785 MEDLINE
- (38) Ratzman, K; Diabetologia 1981, V21, P192
- (39) Reboldi, G; Int J Artif Organs 1991, V14, P350 MEDLINE
- (40) Riccardi, G; Am J Epidemiol 1985, V121, P422 MEDLINE
- (41) Rizza, R; N Engl J Med 1980, V303, P1313 MEDLINE
- (42) Seltzer, H; Diabetes Mellitus: Theory and Practice 1970, P436 HCAPLUS
- (43) Shen, S; J Clin Invest 1970, V49, P2151 HCAPLUS
- (44) Sherwin, R; J Clin Invest 1974, V53, P1481 HCAPLUS
- (45) Thiebaud, D; Diabetes 1982, V31, P957 HCAPLUS
- (46) Walker, M; Am J Physiol 1991, V261, PE304 HCAPLUS

L79 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1998:668068 HCAPLUS

DN 129:287543

TI Diabetes management system and method for controlling blood
glucose

IN Worthington, David R. L.; Brown, Stephen J.

PA Health Hero Network, USA

SO U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 781,278.

CODEN: USXXAM

DT Patent

LA English

IC ICM G01N033-50

NCL 702019000

CC 9-1 (Biochemical Methods)

Section cross-reference(s): 1, 13, 14

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5822715	A	19981013	US 1997-844245	19970418

US 5956501 A 19990921 US 1997-781278 19970110
PRAI US 1997-781278 A2 19970110
AB This invention describes a diabetes management system for predicting a future blood **glucose** value of a patient and for recommending a corrective action to the patient when the future blood **glucose** value lies outside of a target range. The system includes a patient-operated app. for measuring blood **glucose** values and for storing data relating to **insulin** doses administered to the patient. The app. predicts the patient's future blood **glucose** value based upon the patient's current blood **glucose** value, the fraction of **insulin** action remaining from the **insulin** doses, and the patient's **insulin** sensitivity. The app. also dets. the corrective action for the patient when the predicted blood **glucose** value lies outside of a target range. The system also includes a physician computer in communication with the app. for receiving the blood **glucose** values and **insulin** dose data and for calcg. an adjusted **insulin** sensitivity for use in subsequent predictions. The diabetes management system of the present invention provides a significant improvement over conventional diabetes management systems by alerting the patient to the possible development of hypoglycemia or hyperglycemia between meals, thereby allowing the patient to take early corrective action.

ST diabetes management system app blood **glucose**
IT Analytical apparatus
Apparatus
(blood **glucose** analyzer; diabetes management system and method for controlling blood **glucose**)
IT Information retrieval
(computerized; diabetes management system and method for controlling blood **glucose**)
IT **Blood**
Blood analysis
Blood glucose analysis
Computers
Diabetes mellitus
Hyperglycemia
Hypoglycemia
Memory devices
(diabetes management system and method for controlling blood **glucose**)
IT **Blood glucose**
RL: ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(diabetes management system and method for controlling blood **glucose**)
IT **Carbohydrates, biological studies**
RL: BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diabetes management system and method for controlling blood **glucose**)
IT Communication
(telecommunication; diabetes management system and method for controlling blood **glucose**)
IT 50-99-7, D-Glucose, analysis
RL: ANT (Analyte); BOC (Biological occurrence); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(diabetes management system and method for controlling blood **glucose**)
IT 9004-10-8, **Insulin**, biological studies 133107-64-9, **Insulin lispro**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(diabetes management system and method for controlling blood **glucose**)

L79. ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1998:176130 HCAPLUS

DN 128:190152

TI Procedure and device for **patient** specific daily profiles of blood sugar taking into account the effects of **insulin** dosage and diet

IN Salzsieder, Eckhard; Rutscher, Alexander

PA Salzsieder, Eckhard, Germany; Rutscher, Alexander

SO Ger. Offen., 8 pp.

CODEN: GWXXBX

DT **Patent**

LA German

IC ICM G01N033-66

CC 9-1 (Biochemical Methods)

Section cross-reference(s): 18

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19634577	A1	19980305	DE 1996-19634577	19960827
AB	The invention concerns a multistep procedure and device to calc. and interpret the daily blood sugar concn. profile of individuals by using data from blood sugar measurements, insulin dosage, and diet and applying a series of algorithms.				
ST	diabetes device blood sugar insulin diet				
IT	Algorithm Biological simulation Blood glucose analysis Computer application Diabetes mellitus Diabetes mellitus diagnosis Diet Medical goods (procedure and device for patient specific daily profiles of blood sugar taking into account effects of insulin dosage and food intake)				
IT	Diet (therapeutic; procedure and device for patient specific daily profiles of blood sugar taking into account effects of insulin dosage and food intake)				
IT	9004-10-8, Insulin , biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (procedure and device for patient specific daily profiles of blood sugar taking into account effects of insulin dosage and food intake)				

L79. ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1994:404464 HCAPLUS

DN 121:4464

TI **Computer**-controlled OGTT

AU Belfiore, Francesco; Volpicelli, Giovanni; Iannello, Silvia; Campione, Rosa

CS Inst. Clin. Med. I, Univ. Catania Med. Sch., Catania, Italy

SO Front. Diabetes (1993), 12(CURRENT TOPICS IN DIABETES RESEARCH), 76-85

CODEN: FDIADJ; ISSN: 0251-5342

DT Journal

LA English

CC 9-16 (Biochemical Methods)

Section cross-reference(s): 14

AB To measure **insulin** resistance under physiol. conditions, the computer-controlled OGTT was developed which consists of an oral **glucose** load test executed while an **insulin** delivery system infuses **insulin** according to a particular algorithm to force the **glycemic** curve to remain within the normal range of values. Simultaneous measurement of free fatty acids allows evaluation also of the **insulin** resistance concerning blood free fatty acids in addn. to the **insulin** resistance concerning blood

glucose level. The test permits measurement of some important parameters, including: the insulinemic area required to maintain the OGTT **glycemic** curve within normal values even in **diabetic** patients; the whole body **insulin** resistance calcd from the insulinemic, **glycemic**, and free fatty acid areas, according to a given formula; the **insulin** secretory response (as indicated by C-peptide values) to a normal **glycemic** curve; and the time course of the above parameters during the test.

ST computer controlled oral **glucose** tolerance test

IT **Diabetes** mellitus
(computer-controlled oral **glucose** tolerance test in, in humans)

IT **Algorithm**
(for **insulin** infusion during computer-controlled oral **glucose** tolerance test in humans)

IT **Blood sugar**
Fatty acids, biological studies
RL: BIOL (Biological study)
(**insulin** resistance detn. by computer-controlled oral **glucose** tolerance test in relation to, in humans)

IT **9004-10-8, Insulin**, biological studies
RL: BIOL (Biological study)
(resistance to, computer-controlled oral **glucose** tolerance test for detn. of, in humans)

IT **50-99-7, D-Glucose**, biological studies
RL: BIOL (Biological study)
(tolerance test, oral, computer-controlled, in humans)

L79 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1993:18844 HCAPLUS

DN 118:18844

TI Apparatus and method for **glucose** loading test for **diabetes** diagnosis

IN Arita, Seizaburo

PA Japan

SO Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61B010-00

ICS G01N033-50

CC 9-1 (Biochemical Methods)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04256744	A2	19920911	JP 1991-38858	19910212
AB	An app. (or method) for glucose loading test for diabetes diagnosis involves a device (or process) for the input of blood sugar values and insulin values (detd. by the oral sugar loading test) from 0 h to a given period of time, a device (or process) for judging the normal type, borderline type, or diabetic type based on the 2-dimensional diagram of blood sugar values vs. insulin values with respect to time lapses, obtained from the input, and a device (computer) for the output of the result based on the diagram judgement.				
ST	glucose loading test diabetes app				
IT	Mathematics (coordinates, of blood sugar vs. insulin values, in blood sugar loading test, for diabetes diagram)				
IT	Diabetes mellitus (diagram of, blood sugar loading test for, app. and method for, blood sugar vs. insulin coordinates in relation to)				
IT	Computer application (in app. for blood sugar loading test for diabetes diagram, blood sugar vs. insulin coordinates in relation to)				
IT	Blood sugar				

- (loading test, for **diabetes** diagrams, app. and method for, blood sugar vs. **insulin** coordinates in relation to)
- IT **Blood analysis**
(sugar loading test for, for **diabetes** diagrams, app. and method for, blood sugar vs. **insulin** coordinates in relation to)
- IT 50-99-7, **Glucose**, analysis 9004-10-8,
Insulin, analysis
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in blood sugar loading test, app. and method for, blood sugar vs. **insulin** coordinates in relation to)
- L79 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:422839 HCAPLUS
DN 117:22839
TI Cubic spline fit for data of oral **glucose tolerance** test and **insulin** releasing test and their clinical significances
AU Wen, Jianxin; Luo, Hongbin; Liao, Eryuan; Chao, Chusheng; Wu, Hanwen
CS Endocrine Res. Lab., Hunan Med. Univ., Changsha, Peop. Rep. China
SO Hunan Yike Daxue Xuebao (1992), 17(1), 29-32, 36
CODEN: HYXBET
DT Journal
LA Chinese
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 13, 14
- AB The data of the oral **glucose** tolerance test (OGTT) and **insulin**-releasing test (IRT) were fitted with the cubic spline function as well as a microcomputer program. The fitting ability was discussed by a statistical method. The total efficiency of fitting results for the curves of OGTT and IRT were 91 and 79%, resp. It gave 2 equations and a lot of characterized consts. that might be useful for the diagnosis and classification of **diabetes** mellitus. Moreover, it could provide some basic data for the dynamic research of **insulin** secretion.
- ST **diabetes** diagnosis **glucose** tolerance **insulin** release; math function computer program **diabetes** test
- IT **Mathematics**
(cubic spline function, for oral **glucose** tolerance and **insulin** releasing tests in **diabetes** diagnosis)
- IT **Diabetes** mellitus
(diagnosis of, oral **glucose** tolerance and **insulin** releasing tests for, cubic spline function and computer program in)
- IT Computer program
(for oral **glucose** tolerance and **insulin** releasing tests in **diabetes** diagnosis)
- IT 9004-10-8, **Insulin**, biological studies
RL: BIOL (Biological study)
(releasing test for, in diagnosis of **diabetes**, cubic spline function and computer program in)
- IT 50-99-7, **Glucose**, biological studies
RL: BIOL (Biological study)
(tolerance test for, in diagnosis of **diabetes**, cubic spline function and computer program in)
- L79 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:169683 HCAPLUS
DN 116:169683
TI Method for diagnosis of **diabetes** mellitus
IN Korolyuk, I. P.; Bykhovskaya, E. Yü.
PA Kuibyshev State Medical Institute, USSR
SO U.S.S.R.
From: Otkrytiya, Izobret. 1991, (33), 163.
CODEN: URXXAF
DT Patent
LA Russian
IC ICM G01N033-68

CC 9-16 (Biochemical Methods)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1675774	A1	19910907	SU 1985-3907691	19850610
AB	In a glucose tolerance test for diabetes mellitus, immunoreactive insulin and the content of C-peptide in both plasma and erythrocytes are detd. A math. formula is given for an index for diagnosis of diabetes .				
ST	diabetes diagnosis insulin C peptide; math equation				
IT	diabetes diagnosis				
IT	Blood analysis (C-peptide detn. in, in diabetes mellitus diagnosis)				
IT	Erythrocyte (C-peptide in plasma and, in diabetes mellitus diagnosis)				
IT	Diabetes mellitus (diagnosis of, glucose tolerance test for, C-peptide and immunoreactive insulin detn. in)				
IT	Mathematics (equations, for diabetes mellitus diagnosis)				
IT	9004-10-8, Insulin , analysis RL: ANST (Analytical study) (detn. of glucose tolerance and immunoreactive, , in diabetes mellitus diagnosis)				
IT	50-99-7, Glucose , analysis RL: ANST (Analytical study) (detn. of tolerance of, in diabetes mellitus diagnosis)				
IT	59112-80-0, c-Peptide RL: ANT (Analyte); ANST (Analytical study) (detn. of, in plasma and erythrocyte, in diabetes mellitus diagnosis)				

L79 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2001 ACS

AN 1988:507352 HCAPLUS

DN 109:107352

TI The degree and the rate of **glucose** absorption from carbohydrate-containing food and in oral **tolerance** test

AU Dreval, A. V.

CS IMMI, Moscow, USSR

SO Lab. Delo (1988), (6), 33-8

CODEN: LABDAZ; ISSN: 0023-6748

DT Journal

LA Russian

CC 9-15 (Biochemical Methods)

Section cross-reference(s): 14

AB Math. equations are presented and discussed for identifying parameters of **glucose** kinetics under carbohydrate loading test which consider prodn. of **glucose** by the liver. These allow calcn. of the degree and the rate of **glucose** absorption in an oral **glucose** tolerance test and during intake of carbohydrate-contg. food-product. The relative bioavailability of **glucose** from ice cream did not exceed 50%, which allows its use in the diets of persons with **diabetes** mellitus. The liver uptake of **glucose** was .apprx.60% in oral **glucose** tolerance test and its half-absorption period was 10.6 min.

ST **glucose** absorption oral tolerance test; **diabetes****glucose** absorption oral tolerance testIT **Diabetes** mellitus(math. equations for study of **glucose** absorption during oral tolerance test in relation to)

IT Biological transport

(absorption, of **glucose**, during oral tolerance test, math. equations for study of)IT **Mathematics**(equations, for **glucose** absorption study during oral tolerance test)

- IT 50-99-7, **Glucose**, biological studies
 RL: BIOL (Biological study)
 (absorption of, during oral tolerance test, math. equations for study of)
- L79 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2001 ACS
 AN 1981:477730 HCAPLUS
 DN 95:77730
 TI Correlation between **glycemic** and **insulin** curves
 AU Balsano, Francesco; Bonavita, M. Simona; Cumo, Maurizio; Ferrari, Giuseppe
 CS Policlin. "Umberto I", Univ. Roma, Rome, 00100, Italy
 SO Quad. Sclavo Diagn. Clin. Lab. (1981), 17(2), 216-29
 CODEN: QSDCAJ; ISSN: 0033-4979
 DT Journal
 LA English
 CC 13-5 (Mammalian Biochemistry)
 AB A math. model is presented for the relation between blood sugar and **insulin** curves after a given **glucose** dose. The model which gave the best representation for the exptl. data is that the rate of **insulin** consumption is directly proportional to the **glycemic** level. This was deduced from a simple functional relation dependent upon elementary biophys. mechanisms. This model will aid in the rapid formulation of an **insulin** curve from a given blood sugar curve.
 ST **glucose insulin** blood model
 IT **Simulation model**
 (for **glucose** and **insulin** of blood)
 IT **Blood sugar**
 (**glucose** effect on, model for, **insulin** in relation to)
 IT **Blood**
 (**insulin** of, **glucose** effect on, model for)
 IT 50-99-7, biological studies
 RL: BIOL (Biological study)
 (blood sugar and **insulin** response to, model for)
 IT 9004-10-8, biological studies
 RL: BIOL (Biological study)
 (of blood, **glucose** effect on, model for)
- L79 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2001 ACS
 AN 1980:53726 HCAPLUS
 DN 92:53726
 TI A **theoretical model** to **predict** the behavior of glycosylated hemoglobin levels
 AU Beach, Kirk W.
 CS Dep. Surg., Univ. Washington, Seattle, WA, 98195, USA
 SO J. Theor. Biol. (1979), 81(3), 547-61
 CODEN: JTBIAP; ISSN: 0022-5193
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 Section cross-reference(s): 13, 14
 AB The measurement of glycosylated Hb as a percentage of total Hb is rapidly becoming the std. method of monitoring the av. blood sugar level in **diabetics**. Speculation exists in the literature about the nature of the glycosylation reaction. Most experimenters expect a linear relation between the plasma **glucose** level and percent glycosylated Hb in whole blood; however, a curve of decreasing slope with increasing **glucose** concn. is found. A reaction model including simple 1st order kinetics between **glucose** and Hb and a finite erythrocyte life of 120 days is considered. By carrying out the integration for each erythrocyte cohort followed by an integration combining all cohorts, a curve corresponding to the exptl. result is found. In addn., results on expected glycosylated Hb percent as a function of erythrocyte age and plasma **glucose** concn. are

presented as well as a plot of **glucose** concn. vs. glycosylated Hb percent for the 40-day erythrocyte life in mice. All of the results correlate with exptl. values in the literature if a rate const. of $k = 1.0 \times 10^{-5}$ dL mg⁻¹ day is used. The evaluation of a published radioactive iron-transferrin expt. reveals the possibility that the glycosylation reaction begins during erythropoiesis. Finally, a curve is displayed which shows the expected 120-day decay during **normoglycemia**, of an elevated glycosylated Hb level resulting from a preceding period of const. **hyperglycemia**.

ST glycosylated Hb model **diabetes**
 IT **Simulation model**
 (for glycosylated Hb levels, in **diabetes**)
 IT **Hyperglycemia**
 (glycosylated Hb level and blood sugar in **diabetes** in relation to)
 IT **Blood sugar**
 (glycosylated Hb levels in relation to, in **diabetes**, simulation of)
 IT **Erythrocyte**
 (glycosylated Hb levels in, in **diabetes**, simulation of)
 IT **Diabetes mellitus**
 (glycosylated Hb levels in, simulation of, blood **glucose** in relation to)
 IT Hemoglobins
 RL: BIOL (Biological study)
 (glycosylated, simulation of levels of, blood **glucose** in **diabetes** in relation to)

L79 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2001 ACS
 AN 1979:529009 HCAPLUS
 DN **91:129009**
 TI **Algorithm** for extracorporeal blood **glucose** regulation
 AU Kruse-Jarres, J. D.; Bresch, M.; Lehmann, U.
 CS Klin.-Chem. Exp. Lab., Chirurg. Universitaetsklin. Freiburg/Br., Freiburg/Br., Fed. Rep. Ger.
 SO J. Clin. Chem. Clin. Biochem. (1979), 17(7), 465-9
 CODEN: JCCBDT; ISSN: 0340-076X
 DT Journal
 LA German
 CC 63-7 (Pharmaceuticals)
 Section cross-reference(s): 9
 AB A control mechanism is described, based on a simple proportional-differential regulation. The calcn. takes 1 min, and it takes into account **glucose** degrdn., **insulin** half-life in vivo, and the delay between blood sampling and **insulin** action on the blood **glucose** value. This is repeated continuously every minute (short-time mode) or every 5 min or more (long-time mode), depending on the rate of change of the blood **glucose**. Operator decision is based on digitally converted tables, which are analogous to the graph of proportional control, and on **glucose** equiv. tables, which give **insulin** effect on **glucose** as a function of time.
 ST blood sugar extracorporeal regulation computer; **insulin** blood sugar computer; artificial pancreas blood sugar computer
 IT **Diabetes mellitus**
 (artificial pancreas in, algorithm for blood **glucose** extracorporeal regulation in relation to)
 IT **Algorithm**
 (for blood **glucose** extracorporeal regulation)
 IT **Blood sugar**
 (regulation of, extracorporeal, computer program for)
 IT Computer application
 (to blood sugar extracorporeal regulation, with artificial pancreas)
 IT Pancreas
 (artificial, blood sugar extracorporeal regulation by, computerized)
 IT 9004-10-8, biological studies
 RL: BIOL (Biological study)

(blood sugar regulation with, computerized extracorporeal regulation in relation to)

L79 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2001 ACS
 AN 1978:439926 HCAPLUS
 DN 89:39926
 TI Derivation and experimental proof of a new **algorithm** for the artificial B-cell based on the **individual analysis** of the physiological **insulin-glucose** relationship
 AU Fischer, U.; Jutzi, E.; Freyse, E. J.; Salzsieder, E.
 CS Cent. Inst. Diabetes "Gerhardt Katsch", Karlsburg, E. Ger.
 SO Endokrinologie (1978), 71(1), 65-75
 CODEN: ENDKAC; ISSN: 0013-7251
 DT Journal
 LA English
 CC 13-2 (Mammalian Biochemistry)
 Section cross-reference(s): 2, 14
 AB Normal dogs were submitted to oral **glucose** loads or to i.v. **glucose** infusions. **Insulin** secretion rates (CISR) were calcd. considering the resulting peripheral venous concn. differences in short intervals and the exptl. detd. half life and apparent distribution space of exogenous **insulin**. Multiple regression anal. was done between CISR and both the level and the rate of change of plasma **glucose**. The regression coeffs. were used as algorithm parameters for continuous plasma **glucose**-dependent i.v. **insulin** administration in the same animals after induction of an **insulin**-dependent **diabetes**. Normal **glycemic** regulation over the day could be restored by this system. The **insulin** responsiveness, however, varied from day to day. By using this **insulin** dosage pattern, nearly normal plasma **glucose** curves and slightly elevated **insulin** reactions after **glucose** loading were obsd. This kind of algorithm could also be used in **diabetic** humans.
 ST **insulin** secretion math model
 IT **Algorithm**
 (for **insulin** continuous therapy in **diabetes** mellitus)
 IT **Blood sugar**
 (**insulin** secretion in response to, math model for)
 IT **Diabetes** mellitus
 (**insulin** therapy in, continuous, algorithm for)
 IT 9004-10-8, biological studies
 RL: BIOL (Biological study)
 (secretion of, in response to blood sugar, math model for)

=> fil biosis

FILE 'BIOSIS' ENTERED AT 09:16:10 ON 26 NOV 2001
 COPYRIGHT (C) 2001 BIOSIS(R)

FILE COVERS 1969 TO DATE.
 CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
 FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 21 November 2001 (20011121/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> d all tot

L98 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1994:16062 BIOSIS
 DN PREV199497029062
 TI Mathematical methods to **calculate** the glycemic index of carbohydrate food load in patients with insulin-dependent diabetes

mellitus.

AU Dreval', A. V.; Batashova, M. G.
 CS Inst. Nutr., Acad. Med. Sci. Russ., Moscow Russia
 SO Problemy Endokrinologii, (1993) Vol. 39, No. 3, pp. 13-18.
 ISSN: 0375-9660.
 DT Article
 LA Russian
 SL English
 AB The authors analyze the methodologic problem of calculating the glycemic indexes in patients with insulin-dependent diabetes mellitus (IDDM) administered substitution insulin therapy. They demonstrate that postalimentary glycemic curves in IDDM may essentially differ from those in health. Eight characteristic types of postalimentary glycemic curves observed in IDDM patients were singled out, and simple and therefore fairly available for clinicians methods of automated (making use of programmed microcalculators) calculation of the glycemic indexes have been developed for each of these types. Interpretations of abnormal curves are suggested as are possible approaches to an analysis of such data. The authors believe that the developed methods of calculation of glycemic indexes will help rapidly create a Russian data bank of foodstuffs recommended for diabetics.

CC **Mathematical Biology and Statistical Methods *04500**
 Clinical Biochemistry; General Methods and Applications *10006
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Biophysics - Biocybernetics *10515
 Pathology, General and Miscellaneous - Therapy *12512
Metabolism - Carbohydrates *13004
 Metabolism - Proteins, Peptides and Amino Acids *13012
Nutrition - Carbohydrates *13220
 Food Technology - Evaluations of Physical and Chemical Properties *13530
 Endocrine System - Pancreas *17008

BC Hominidae *86215
 IT Major Concepts
 Clinical Chemistry (Allied Medical Sciences); Endocrine System
 (Chemical Coordination and Homeostasis); Foods; Mathematical Biology
 (Computational Biology); Metabolism; Models and Simulations
 (Computational Biology); Nutrition; Pathology

IT Chemicals & Biochemicals
 INSULIN

IT Miscellaneous Descriptors
 DIET; PROGRAMMED MICROCALCULATOR

ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name
 human (Hominidae)

ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

RN **9004-10-8 (INSULIN)**

L98 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2001 BIOSIS
 AN 1981:181811 BIOSIS
 DN BA71:51803
 TI **DIAGNOSTIC VALUE OF THE ORAL GLUCOSE TOLERANCE TEST
 EVALUATED WITH A MATHEMATICAL MODEL.**
 AU JANSSON L; LINDSKOG L; NORDEN N E; CARLSTROM S; SCHERSTEN B
 CS DEP. CLINICAL CHEM., UNIV. HOSP., LUND, SWEDEN.
 SO COMPUT BIOMED RES, (1980) 13 (6), 512-521.
 CODEN: CBMRB7. ISSN: 0010-4809.
 FS BA; OLD
 LA English
 AB The dynamics of the blood glucose concentration during the oral glucose tolerance test are different from normal in at least 96% of patients with diabetes mellitus. This is shown by using stepwise linear discriminant analysis and a **mathematical model** of the glucose homeostasis for the analysis of the glucose curves in 378 cases. The

mathematical model gives an estimate of the rate of intestinal glucose resorption, and this information was used to significantly improve the discrimination between diabetes mellitus and the normal state. The same estimate was useful for the detection of oxyhyperglycemia and malabsorption. The effect of age on glucose tolerance was included in the discriminant analysis. The intra-individual biological variation in cases with borderline glucose tolerance was 11%.

CC **Mathematical Biology and Statistical Methods *04500**
 Clinical Biochemistry; General Methods and Applications *10006
 Comparative Biochemistry, General 10010
 Biochemical Studies - Carbohydrates 10068
 Biophysics - Biocybernetics *10515
Metabolism - Carbohydrates *13004
 Metabolism - Metabolic Disorders *13020
Nutrition - Malnutrition; Obesity 13203
 Digestive System - Physiology and Biochemistry 14004
 Digestive System - Pathology 14006
Endocrine System - Pancreas *17008
 Developmental Biology - Embryology - Morphogenesis, General 25508
 BC Hominidae 86215
 IT Miscellaneous Descriptors
 HUMAN DIABETES MELLITUS OXY HYPER GLYCEMIA INTESTINAL GLUCOSE
 RESORPTION MAL ABSORPTION AGE EFFECT
 RN 50-99-7 (GLUCOSE)

=> d his

(FILE 'HOME' ENTERED AT 07:46:33 ON 26 NOV 2001)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:46:44 ON 26 NOV 2001

L1 1 S 50-99-7
 L2 1 S INSULIN/CN

FILE 'HCAPLUS' ENTERED AT 07:47:00 ON 26 NOV 2001

L3 116445 S L1
 L4 69479 S L2
 E HOCKERSMITH L/AU
 E INSTRUMENTATION/PA,CS
 E INSTRUMENTATION METRIC/PA,CS
 L5 13 S E5-E8
 L6 5 S L3,L4 AND L5
 L7 8 S (GLUCOSE OR INSULIN) AND L5
 L8 1 S L6 AND ?DIABET?
 L9 0 S L6 AND (?GLYCEM? OR ?GLYCAEM? OR ?GLYCEAM?)
 L10 1 S L6,L7 AND L8

FILE 'BIOSIS' ENTERED AT 07:53:41 ON 26 NOV 2001
 E HOCKERSMITH/AU

FILE 'MEDLINE' ENTERED AT 07:53:58 ON 26 NOV 2001
 E HOCKERSMITH/AU

FILE 'HCAPLUS' ENTERED AT 07:54:14 ON 26 NOV 2001

E CARBOHYDRATE/CW
 L11 75757 S E3,E4
 E CARBOHYDRATE/CT
 L12 1045347 S E25+NT
 E E11+ALL
 E E2
 L13 42853 S E16
 L14 42767 S E66-E82
 L15 32200 S E83-E101
 L16 116445 S L11-L15 AND L3
 L17 30872 S L11-L15 AND L4

L18 164984 S L11-L15 AND GLUCOSE
 L19 40905 S L11-L15 AND INSULIN
 L20 180875 S L16-L19
 E MATHEMATIC/CT
 E E5+ALL
 L21 46 S L20 AND E3-E5
 L22 295 S L20 AND E2+NT
 L23 337 S L21,L22
 E BLOOD ANALYSIS/CT
 E E3+ALL
 L24 107304 S E3,E2+NT
 L25 499857 S E8+NT OR E9+NT OR E10+NT
 L26 88 S L23 AND L24
 L27 27 S L23 AND L25
 L28 102 S L26,L27
 E CALIBRATION/CT
 E E3+ALL
 L29 4119 S E1+NT
 E E7+ALL
 L30 20 S L29 AND L23
 L31 107 S L28,L30
 E SIMULATION/CT
 E E8+ALL
 L32 67604 S E3-E6,E2+NT
 E SIMULATION/CT
 L33 191224 S E3+NT OR E5+NT OR E20+NT OR E35+NT
 L34 1315 S E55+NT
 L35 1786 S L20 AND L32-L34
 L36 127 S L35 AND L24,L25
 L37 450 S L23,L31,L36
 L38 32 S L37 AND (17 OR 18)/SC,SX
 L39 5 S L38 AND (9 OR 18)/SC
 L40 1 S L39 AND P/DT
 L41 76 S L37 AND (?DIABET? OR ?GLYCEM? OR ?GLYCAEM?)
 L42 75 S L41 NOT L38
 L43 56 S L42 AND (ALGORITHM? OR METHOD? OR ASSESSMENT OR GRAPH? OR CUR
 L44 1 S L42 AND INDIVIDUAL ANALYSIS
 L45 148 S L37 AND 9/SC NOT L10,L40,L43,L44,L42
 L46 4 S L45 AND BIOLOGICAL FLUID
 L47 18 S L45 AND (NONINVAS? OR NON INVAS?)
 L48 18 S L45 AND (MODEL OR REFERENCE)/TI
 L49 0 S L37 AND 9/SC NOT L10,L4,L42-L44,L45
 L50 3 S L37 AND 18/SC,SX
 L51 1 S L50 AND PATIENT
 L52 2 S L10,L40,L51
 L53 56 S L43,L44 NOT L52
 SEL DN 4 8 18 21-23 31-33,35,40,53-56
 L54 15 S L53 AND E1-E15
 L55 17 S L52,L54
 L56 116445 S L3 AND L11,L12
 L57 13349 S L56 AND L24,L25
 L58 87 S L57 AND L23
 L59 40 S L57 AND L29
 L60 93 S L57 AND L32-L34
 L61 195 S L58-L60
 L62 140 S L61 AND (9 OR 18)/SC,SX
 L63 55 S L61 NOT L62
 L64 8 S L63 AND (CONTROL? OR QUANTI? OR THERAP?)/TI
 L65 1 S L64 AND (MODEL AND INSULIN AND GLUCOSE AND SECRETION?)/TI
 L66 70 S L62 NOT L45
 L67 37 S L66 NOT L42
 L68 18 S L55,L65
 L69 1689 S L1(L) (ANST/RL OR ANT/RL) AND L11
 L70 120 S L69 AND L24,L25
 L71 13 S L69 AND L23
 L72 5 S L69 AND L32-L35

L73 125 S L70-L72 NOT L42,L45,L53,L61
L74 0 S L73 AND 18/SC,SX
L75 17 S L73 AND 17/SC,SX
L76 109 S L73 AND 9/SC,SX
L77 10 S L73 NOT L75,L76
SEL DN L76 32
L78 1 S E16
L79 19 S L68,L78 AND L3-L10,L11-L78

FILE 'REGISTRY' ENTERED AT 09:03:43 ON 26 NOV 2001

FILE 'HCAPLUS' ENTERED AT 09:03:55 ON 26 NOV 2001

FILE 'BIOSIS' ENTERED AT 09:04:17 ON 26 NOV 2001

L80 139102 S L1
L81 130344 S L2
L82 1941 S L80,L81 AND *04500/CC
L83 1160 S L82 AND 13004/CC
L84 91 S L82 AND 13220/CC
L85 17 S L82 AND 13218/CC
L86 78 S L83 AND L84,L85
L87 1 S L86 AND CALCULATE/TI
L88 29 S L84-L85 NOT L86
L89 939 S L82 AND 17008/CC
L90 233 S L82 AND 22016/CC
L91 952 S L89,L90
L92 707 S L91 AND L83-L85 NOT L86,L88
L93 100 S 132?/CC AND L92
L94 15 S L93 AND MATHEMAT? MODEL?
L95 4 S L94 NOT AB/FA
L96 11 S L94 NOT L95
L97 1 S L96 AND DIAGNOS? VALUE
L98 2 S L87,L97

FILE 'BIOSIS' ENTERED AT 09:16:10 ON 26 NOV 2001
SET COST ON